BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    

FemmePharma Global Healthcare, Inc. Opens Investigational New Drug Application For Treatment Of Breast Pain

3/27/2006 10:54:39 AM

WAYNE, Pa., March 27 /PRNewswire/ -- FemmePharma Global Healthcare, Inc., a suburban Philadelphia-based pharmaceutical company focusing on developing treatments for diseases and disorders suffered by women, opened an Investigational New Drug application for the treatment of breast pain. Clinical trials are expected to commence in the fourth quarter of 2006.

The development of a treatment to alleviate breast pain comes at the heels of the company's previous success at developing a treatment that lessens the severe discomfort caused by endometriosis. FemmePharma Global Healthcare developed its treatment for endometriosis using a unique, patented platform technology that eliminates systemic side effects by concentrating a small but effective amount of the drug directly to a targeted area of the disease or disorder.

The company is now engineering its patented platform technology to develop a topical cream to treat breast pain because side effects caused by the few current treatment options are seriously objectionable. "If a women goes to her physician today for medication to help relieve breast pain she likely will be faced with several inferior choices: an FDA-approved prescription medication that typically causes unpalatable side effects like facial hair growth, weight gain and acne; or an over-the-counter pain reliever that does not address the underlying causes of breast pain," said Gerianne Tringali DiPiano, President and CEO of FemmePharma Global Healthcare.

"The lack of an effective and safe treatment for breast pain is why FemmePharma Global Healthcare has developed a convenient, topical treatment that should diminish side effects and achieve efficacy," added Dr. Peter Mays, Vice President, Pharmaceutical Development of FemmePharma Global Healthcare.

On the whole, breast pain is a widespread problem. Roughly 26 million women complain of the disorder, and about 15 percent of women experience symptoms severe enough to warrant medication. Breast pain remains seriously debilitating and can cause its victims to miss work, withdraw from everyday activities, and recoil from intimacy. Sometimes the pain is so severe that a woman may even avoid hugging her children.

FemmePharma Global Healthcare's efforts to create an effective treatment that yields no harmful side effects could offer long-awaited relief for those women who suffer sharp, stabbing, burning, chronic pain.

According to Tringali DiPiano, female patients are often given cursory, ineffective advice on how to cope with the pain or are treated as if the disorder is a phantom pain. "Breast pain produces stress and anxiety as women are concerned about the underlying causes of the pain. Even more concerning, breast pain is a leading reason why physicians overprescribe mammographies for young women," said Tringali DiPiano.

Founded in 1996, FemmePharma Global Healthcare is focused on developing safe and effective drugs minimizing or eliminating the side effects associated with many drug therapies by designing treatments in a way that suits the female anatomy. The company has already scored great success with developing a safe and effective treatment for endometriosis. After successfully completing Phase 2 studies for this product, it was acquired by KV Pharmaceutical who will continue its development and bring the drug to market. Other current endeavors include a product to treat urinary incontinence in Phase 2 clinical trials, and products to treat dysmenorrhea and dysfunctional uterine bleeding in preclinical development.

For more information, visit or call 610-995-0801.

Contact: Lori Iller, 215-884-6499.

FemmePharma Global Healthcare, Inc.

CONTACT: Lori Iller, +1-215-884-6499, for FemmePharma

Read at